09:49 AM EST - Cardiome Pharma Corp. : and SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs, today announced an exclusive license and supply agreement for Cardiome to commercialize Trevyent® in certain regions outside the U.S. if Trevyent is approved for the treatment of pulmonary arterial hypertension, or PAH, in such regions. Cardiome Pharma Corp.
shares T.COM are trading unchanged at $11.57.
